Skip to main content

Peer Review reports

From: Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis

Original Submission
7 Apr 2023 Submitted Original manuscript
1 May 2023 Reviewed Reviewer Report
4 May 2023 Reviewed Reviewer Report
4 May 2023 Reviewed Reviewer Report
4 May 2023 Reviewed Reviewer Report - Antonis Valachis
28 Jun 2023 Author responded Author comments - Amin Haiderali
Resubmission - Version 2
28 Jun 2023 Submitted Manuscript version 2
3 Jul 2023 Author responded Author comments - Amin Haiderali
Resubmission - Version 3
3 Jul 2023 Submitted Manuscript version 3
7 Jul 2023 Reviewed Reviewer Report
18 Jul 2023 Reviewed Reviewer Report - Antonis Valachis
18 Jul 2023 Reviewed Reviewer Report
31 Jul 2023 Author responded Author comments - Amin Haiderali
Resubmission - Version 4
31 Jul 2023 Submitted Manuscript version 4
4 Aug 2023 Reviewed Reviewer Report - Antonis Valachis
11 Aug 2023 Reviewed Reviewer Report
Resubmission - Version 5
Submitted Manuscript version 5
Publishing
12 Aug 2023 Editorially accepted
23 Aug 2023 Article published 10.1186/s12885-023-11293-4

You can find further information about peer review here.

Back to article page